Welcome to our dedicated page for Zero Candida Technologies news (Ticker: ZCTFF), a resource for investors and traders seeking the latest updates and insights on Zero Candida Technologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zero Candida Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zero Candida Technologies's position in the market.
Zero Candida Technologies (OTCQB: ZCTFF) announced a design freeze for its ZC-001 AI-enabled therapeutic device and has begun prototype production on Oct 20, 2025. The company started manufacturing 50 prototype units with completion expected by Q1 2026. The design freeze finalizes device and SMART docking case specifications and sets technical standards for validation and regulatory pathway progression.
Key features include blue light therapy, targeted drug delivery, wireless diagnostics with encrypted data transmission, docking alignment for charging and dosing accuracy, medical-grade materials, and modular assembly for scalable manufacturing.
Zero Candida Technologies (OTCQB: ZCTFF), a Femtech company developing an AI-powered medical device for women's gynecological health, reported its Q2 2025 financial results. The company reported a Q2 operating loss of $0.31 million, improved from $0.35 million in Q2 2024, while cash position strengthened to $0.46 million from $0.24 million at year-end 2024.
The company outlined key development milestones including final preclinical results by Q2 2026, laboratory validation studies in Q3 2026, pilot clinical trials in Israel by Q4 2026, and U.S. targeted clinical trials by Q3 2027. Management confirms sufficient resources to support operations for the next 12 months, with working capital of $1.53 million and total assets of $2.77 million.
Zero Candida Technologies (OTCQB: ZCTFF), a FemTech medical device company, has announced two key developments: achieving DTC eligibility for its common shares and an upcoming presentation at the OTCQB Venture Virtual Investor Conference on August 7th, 2025.
The DTC eligibility enables electronic clearing and settlement of shares in the United States, improving trading efficiency and reducing settlement times. This development aims to enhance liquidity and reduce transaction costs while making shares more accessible to U.S. investors, particularly institutions requiring DTC eligibility.
Zero Candida Technologies (ZCTFF) reported its full-year 2024 financial results, marking a transformative year with key achievements. The company completed its public listing and achieved important pre-clinical milestones for its women's health medical device.
Financial highlights include:
- R&D expenses: CAD 1,276,000 (vs CAD 1,868,000 in 2023)
- G&A expenses: CAD 965,000 (vs CAD 649,000 in 2023)
- Operating loss: CAD 6,241,000 (vs CAD 2,517,000 in 2023)
- Net loss: CAD 6,283,000 (vs CAD 2,513,000 in 2023)
- Cash position: CAD 3,052,000 (vs CAD 1,639,000 in 2023)
Key 2024 developments include successful completion of a reverse merger acquisition for CAD 4 million, listing on TSXV, obtaining a final patent in South Africa for the ZC-01 device, and receiving positive pre-clinical safety study results from Shamir Medical Centre.
Zero Candida Technologies (ZCTFF) has announced the commencement of trading on the OTCQB Venture Market under the ticker symbol 'ZCTFF', while maintaining its listings on the TSX Venture Exchange and Frankfurt Stock Exchange.
The OTCQB, operated by OTC Markets Group and recognized by the SEC, serves as a premier market for early-stage and development-stage companies. Listed companies must maintain current financial reporting, meet compliance requirements, and complete annual verification processes.
CEO Eli Ben Haroosh highlighted this milestone as strategic for the company's long-term growth, emphasizing their focus on expanding market presence and partnerships. The listing aligns with their recent patent advancements and aims to capitalize on the growing VVC treatment market, particularly in the U.S.
FAQ
What is the current stock price of Zero Candida Technologies (ZCTFF)?
